Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by IMARA Inc. on June 2, 2022. The filing details the results of votes submitted to security holders regarding director elections and the ratification of the independent auditor. Note: The request metadata references "Enliven Therapeutics, Inc.", but the filing text explicitly identifies the registrant as IMARA Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Director Elections (Class II)
Stockholders elected two Class II directors for three-year terms expiring at the 2025 Annual Meeting:
- Rahul D. Ballal, Ph.D.: 11,789,401 votes For; 1,791,276 votes Withheld; 5,332,673 Broker Non-Votes.
- Barbara J. Dalton, Ph.D.: 11,786,912 votes For; 1,793,765 votes Withheld; 5,332,673 Broker Non-Votes.
Auditor Ratification
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022:
- Votes For: 18,806,373
- Votes Against: 60,227
- Votes Abstaining: 46,749
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the correct registrant name is IMARA Inc. (trading symbol IMRA), not Enliven Therapeutics, Inc.
- Confirm the successful election of Rahul D. Ballal and Barbara J. Dalton to the Board of Directors.
- Note the significant number of broker non-votes (over 5.3 million) associated with the director elections.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2022 fiscal year.